作者
Uwe Marx, Takafumi Akabane, Tommy B Andersson, Elizabeth Baker, Mario Beilmann, Sonja Beken, Susanne Brendler-Schwaab, Murat Cirit, Rhiannon David, Eva-Maria Dehne, Isabell Durieux, Lorna Ewart, Suzanne C Fitzpatrick, Olivier Frey, Florian Fuchs, Linda G Griffith, Geraldine A Hamilton, Thomas Hartung, Julia Hoeng, Helena Hogberg, David J Hughes, Donald E Ingber, Anita Iskandar, Toshiyuki Kanamori, Hajime Kojima, Jochen Kuehnl, Marcel Leist, Bo Li, Peter Loskill, Donna L Mendrick, Thomas Neumann, Giorgia Pallocca, Ivan Rusyn, Lena Smirnova, Thomas Steger-Hartmann, Danilo A Tagle, Alexander Tonevitsky, Sergej Tsyb, Martin Trapecar, Bob Van de Water, Janny Van den Eijnden-van Raaij, Paul Vulto, Kengo Watanabe, Armin Wolf, Xiaobing Zhou, Adrian Roth
发表日期
2020
期刊
Altex
卷号
37
期号
3
页码范围
365
出版商
NIH Public Access
简介
The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human in vitro (patho) biology and, therefore, to provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Currently, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which say this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches neither have been widely adopted by the pharmaceutical industry yet nor have they reached regulated drug authorization processes.
学术搜索中的文章
U Marx, T Akabane, TB Andersson, E Baker… - Altex, 2020